Fidaxomicin versus Conventional Antimicrobial Therapy in 59 Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation with Clostridium difficile-Associated Diarrhea
Authors:
Open Access
- 1 September 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (9) , 4501-4505
Abstract
The feasibility of fidaxomicin versus vancomycin and metronidazole (conventional therapy) was assessed in 59 transplant recipients with 61 episodes of Clostridium difficile -associated diarrhea (CDAD). Overall clinical cure was achieved in 86% of episodes, and in 7% of episodes, infection recurred. Fidaxomicin was well tolerated. Clinical cures were not significantly different compared with conventional therapy (67% versus 89%, respectively; P = 0.06). Univariate analysis of predictors for lack of clinical cure included continued use of broad-spectrum systemic antibiotics ( P = 0.026) and prior diagnosis of CDAD (95% confidence interval, 1.113 to 19.569; odds ratio, 4.667; P = 0.041). New-onset vancomycin-resistant Enterococcus (VRE) colonization was not noted after fidaxomicin therapy alone. However, this occurred in 10 of 28 patients (36%) following conventional therapy, and 2 of 3 patients with subsequent bacteremia died.Keywords
This publication has 14 references indexed in Scilit:
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled TrialsClinical Infectious Diseases, 2012
- Epidemiology and Outcomes of Clostridium difficile Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2012
- Clostridium difficile infection in HIV-seropositive individuals and transplant recipientsJournal of Infection, 2012
- Comparative Effectiveness of Clostridium difficile TreatmentsAnnals of Internal Medicine, 2011
- Fidaxomicin versus Vancomycin forClostridium difficileInfectionNew England Journal of Medicine, 2011
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycinMicrobiology, 2010
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile InfectionAntimicrobial Agents and Chemotherapy, 2009
- Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?Bone Marrow Transplantation, 2008
- Early and late onset Clostridium difficile-associated colitis following liver transplantationTransplant International, 2007
- Relationship of Colonization with Vancomycin-Resistant Enterococci and Risk of Systemic Infection in Patients with CancerClinical Infectious Diseases, 2006